Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
PODD · Nasdaq · United States · Surgical & Medical Instruments & Apparatus
In shortINSULET CORP is profitable, generates cash and carries moderate debt, with revenue growing (+30.7% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 17.5% | 75/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 9.1% | 56/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 18.1% | 91/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 14.0% | 93/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.81× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.63× | 76/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 0.41× | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 7.98× | 62/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 4.78 | 94/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 13.9% | 76/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.53× | 100/100 |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 5.4% | 91/100 |
| Operating margin volatility | 5.5% | 59/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 27.5% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | 267.7% | 100/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 1,099 | 1,305 | 1,697 | 2,072 | 2,708 |
| Cost of revenue | 347 | 500 | 537 | 626 | 768 |
| Gross profit | 752 | 806 | 1,160 | 1,446 | 1,940 |
| Research & development | 160 | 180 | 205 | 220 | 301 |
| Selling, general & admin | 466 | 588 | 735 | 917 | 1,165 |
| Operating income | 126 | 38 | 220 | 309 | 474 |
| Interest expense | 62 | 36 | 36 | 43 | 59 |
| Pre-tax income | 21 | 9.8 | 215 | 300 | 340 |
| Income tax | 3.7 | 5.2 | 8.3 | (118) | 92 |
| Net income | 17 | 4.6 | 206 | 418 | 247 |
| Diluted EPS | $0.24 | $0.07 | $2.94 | $5.78 | $3.48 |
| Diluted shares (millions) | 69 | 70 | 74 | 74 | 72 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
4.78 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026